Amgen freaked out and pulled plug on brodalumab too quickly

European Ad Comm backs AstraZeneca's psoriasis med brodalumab
May 19, 2017 2:50 PM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion backing approval of AstraZeneca's (AZN -0.2%) IL-17 inhibitor brodalumab for the treatment of adult patients with moderate-to-severe plaque psoriasis.

The marketing application was submitted by licensee LEO Pharma which owns exclusive rights in Europe.

A final decision from the European Commission usually takes ~60 days.

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/brodalumab-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-moderate-to-severe-plaque-psoriasis-19052017.html

 

Amgen is dead in water! Time for acquisitions and layoffs!

 

Good for Valeant and AZ. Amgen's loss.

Amgen spent hundreds of millions on development for other companies profit.

Everyone should partner with Amgen!